Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Can-Therapy Inc. has 1 pending office action currently active in the Biotechnology & Pharmaceuticals technology area. This 1 pending office action is assigned to 1 distinct examiner, YOO, SUN JAE. Because this individual is also the busiest examiner with 1 busiest examiner pending action, the company's current prosecution is entirely centralized. The presence of 1 distinct art unit further indicates that the technical review is confined to a specific division within the office.
Practitioners should note that with 1 distinct examiner and 1 distinct art unit, there is no opportunity to compare different examination styles across the Biotechnology & Pharmaceuticals portfolio. The success of the 1 pending office action relies on addressing the specific requirements of YOO, SUN JAE. This concentration of the 1 busiest examiner pending action means that a single individual's interpretation of Biotechnology & Pharmaceuticals standards will determine the immediate trajectory of the portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YOO, SUN JAE | 1 | 71.2% | +0.3% |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18547822 | NOVEL ADAMANTYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | YOO, SUN JAE | 1621 | §112 | Final Rejection | — | Pending | Nov 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCan-Therapy Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Sun Jae Yoo has the most, with 1 of Can-Therapy Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
